Restenosis remains the bane of percutaneous coronary intervention. Local delivery of radiation, brachytherapy, is a promising therapy for the prevention of restenosis. Animal studies have suggested that brachytherapy may be an effective treatment for preventing restenosis. The type of radiation as well as the doses and delivery systems are currently under study; several clinical trials are underway. This paper reviews the biological basis, including animal studies, of intracoronary brachytherapy as well as the current data from clinical trials.
Introduction
Restenosis remains a major limitation of percutaneous coronary interventions. An estimated 800 000 angioplasties are performed each year in the USA and approximately 40% of these cases will have restenosis within 6 months. When used in appropriate patients, coronary stents may reduce the restenosis rate by half. Numerous devices and a plethora of pharmaceutical strategies have been tried in an effort to mitigate restenosis; with the exception of coronary stents and probucol, none has been shown to have a clearly favorable effect on restenosis. The advent of coronary stenting has led to a new and formidable problem: instent restenosis.
Investigators have recently demonstrated that use of local radiation, in conjunction with coronary interventions, may substantially diminish the rate of restenosis. The therapeutic mechanism is unclear and undoubtedly complex, but it appears that irradiation of the media and cellular component of the adventitia likely reduces neointimal hyperplasia, a major factor in the restenosis process. This paper reviews current knowledge regarding intravascular brachytherapy and its potential role to inhibit restenosis.
Biological considerations
External beam radiation therapy has been used for many 'benign' proliferative disorders including keloids, 1 heterotopic bone formation, 2 pterygia, 3 Graves' ophthalmopathy, 4 gynecomastia, 5 and arteriovenous malformations.
iety of locally delivered radioactive sources has been impressively effective in animal models and preliminary human studies. Examination of radiobiological modeling 7 suggests several mechanisms for the attenuation of the restenosis response after irradiation. It appears that a sufficient percentage of potentially clonogenic smooth muscle cells (SMC) may not survive ionizing radiation, removing the possibility that the surviving SMC could proliferate sufficiently to cause a significant reduction in arterial flow. Data from clinical trials and animal experimentation imply that a minimum therapeutic dose exists. Results from the SCRIPPS trial 8 suggest a minimum therapeutic dose of 8 Gy (prescribed to the inner lumen wall), while Mazur et al 9 found 15 Gy (prescribed to the 0.5 mm within the arterial wall) to be the minimum therapeutic dose. There is also evidence 9, 10 that an artery receiving less than a therapeutic dose actually has an enhanced tendency for proliferation of SMC and consequent restenosis. Excessive exposure of the vessel to radiation can destroy the integrity of the vascular wall and may lead to aneurysms and potential rupture.
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Dosimetry considerations
There are redundant data from animal studies that implicate SMC from the adventitia in the proliferative neointimal response following percutaneous transluminal coronary angioplasty (PTCA). 12, 13 There are also suggestions that progenitor cells from the media may play a role in the restenosis process.
14 Until the target region is clearly identified it seems reasonable to target the adventitia because the media will also be treated in this strategy.
The 'ideal' or minimal therapeutic dose is still unknown. There are multiple variables that change between various trials and animal studies, precluding direct comparisons of minimal therapeutic doses. The position of the source within the artery has an important effect on dosimetryfrequently there is insufficient information to describe accurately the dose distribution within the arterial wall. Intravascular ultrasound (IVUS) has not been used consistently in either animal or human studies; when it has been, dosimetric reconstruction is possible. In studies where centering catheters have been used, one can assume the location of the source. Where centering was not used, the positions of the source wire or source train are assumed to be the same as the position of the ultrasound transducer in the artery. Additionally, different prescription points have been used for various studies.
In order to compare and contrast data from these studies, a method for accurate dose distribution evaluation is needed. Radiation oncologists, biologists, and physicists have suggested various models to describe the biological effect of radiation. Currently, there are no such models for irradiating the coronary arteries; however, models derived from cancer treatment may be extended to intracoronary brachytherapy. With careful design of treatment plans it should be possible to provide a therapeutic dose window where sufficient radiation is delivered to the target while avoiding damage to the adjacent normal tissue.
There is some evidence from clinical trials suggesting that a minimum therapeutic dose exists. For example, the SCRIPPS trial 8 suggested a minimal therapeutic dose of 8 Gy prescribed to the inner lumen wall. There is also evidence provided by Weinberger et al that suggests that a less than therapeutic dose may actually enhance neointimal formation. 10 The potential for damage to the arterial wall and surrounding tissues caused by intracoronary brachytherapy has yet to be established because radiation damage is frequently manifested as a late complication.
The ideal brachytherapy source
The 'best' or 'ideal' source has not been identified. Popowski et al 15 propose that an ideal radioactive source for a workable intracoronary brachytherapy system should: 1) selectively irradiate the targets of the arterial wall, minimizing exposure to surrounding tissue; 2) have adequate dosing within a short application time; 3) have accurate dosimetry; 4) easily conform to the catheterization laboratory protocols; 5) minimize radiation exposure risk for the staff and have no risk of radiation contamination; 6) have easy handling of the radiation source (appropriate t 1/2 allowing transportation, minimal dwell time and repeated use).
We believe the ideal brachytherapy source should deliver a uniform dose to a cylindrical volume 5-6 mm in diameter and 3 cm long for coronary arteries. The dose distribution should also have a sharp fall-off just outside this cylinder, delivering a minimal dose to the surrounding tissue. Lowenergy X-ray sources (such as 125 I or 103 Pd) or high-energy ␤-emitters in the form of a long train of sources (seeds), a single source wire, or perhaps an enclosed tube of radioactive liquid may be optimal for this application. Safety issues have been raised when utilizing liquid sources. The ␤-emitters currently used as sources for intravascular brachytherapy ( 90 Y, 32 P) have lower than optimal mean energies. Dose rate is an important consideration in choosing an ideal source. The source(s) are delivered in a sealed catheter which can reduce or preclude blood flow throughout Vascular Medicine 1999; 4: 257-268 the treated artery -this reduction in flow is substantial and may lead to ischemia during treatment. Short dwell times are therefore desirable to reduce the incidence of ischemia during the irradiation. The efficacy of very low dose rates (achievable with radioactive stents) is currently being tested.
Centering
One of the main advantages of brachytherapy lies in the steep dose gradient this technique affords. Dose from a radioactive source falls off mainly due to two factors: first, the inverse square law, and secondly, the attenuation or absorption of dose by intervening tissue or blood. Without centering it is possible for a source to be in contact with one side of an artery thus overdosing the proximal arterial wall while undertreating the distant wall. In tissue, ␤-particles are more strongly attenuated than even lower energy X-rays -most of the dose is deposited within 1-2 mm of the source. Higher energy X-rays are less abruptly attenuated in tissues and the effects of catheter position are less pronounced. Even with a ␥-emitter such as 192 Ir, it is possible to deliver a dose to the near arterial wall that is three to four times greater than that to the far wall. For example, with an eccentrically placed catheter delivering an 192 Ir source, a minimum therapeutic dose of 8-15 Gy given to the far wall may result in delivering 32-60 Gy to the near wall. While it is not clear what dose levels cause arterial wall damage, delivering a minimal therapeutic dose to the entire arterial wall is likely to be the safest strategy. A centering device allows the minimum dwell time to be used while delivering at least the minimal therapeutic dose to the entire arterial wall.
Shielding
Controversy accompanies the perceived need for specially shielded rooms for intravascular brachytherapy. Since 192 Ir produces photons with a mean energy of 380 KeV, and 1 Ci is a typical source activity for this application, radiation safety standards require catheterization laboratories using this ␥-source to install additional shielding. Pd photon spectra are 28 KeV and 21 KeV, respectively; consequently, the use of either of these sources does not require additional shielding for the catheterization laboratory nor are personnel required to leave during the procedure. Unfortunately, neither 103 Pd nor 125 I are currently available in high enough activities to be considered for these procedures.
Beta-radiation is typically absorbed in a few millimeters of tissue; therefore, additional shielding is not required and catheterization laboratory personnel can safely stay in the room during the procedure. Use of these ␤-emitters also allows the high-dose rate (HDR) afterloader systems to be moved safely from one catheterization laboratory to another.
A single ideal radioactive source may not exist -different sources for peripheral arteries and coronary arteries may be needed. For coronary arteries a high-energy ␤-emitter is ideal, provided it is available in sufficiently high activities. The use of a centering catheter in conjunction with a ␤-emitter can minimize the total dose in these procedures and reduce complications. For target lesions in peripheral arteries, which may be 5 cm or longer and 6-8 mm in diameter, a ␥-source such as 192 Ir may be a better choice. Because of the larger dimensions of these arteries, centering may also be necessary. (Table 1) Several animal models have been used during the development of systems for coronary brachytherapy. Most investigations have relied on a porcine model of restenosis using mechanical stimuli to induce intimal thickening. This model does not truly mimic atherosclerosis and its relevance as a human surrogate is uncertain. Atherosclerotic peripheral arteries of rabbits have also been used as a model, but there are additional questions about the validity of studying a peripheral artery in evaluating human coronary restenosis. Most investigations of vascular brachytherapy have focused on delivery vehicles, dosimetry, and the types of radiation (␤ or ␥). Data from these studies highlight the difficulties in assessing the response to intraarterial radiation with different models.
Animal models
External beam irradiation
Most studies of restenosis rely upon mechanical injury to induce neointimal hyperplasia. Early work in rats suggested that external radiation could potentially inhibit neointimal formation. 34 In a non-atherosclerotic rabbit model, Abbas et al 16 balloon-injured both iliac arteries and then irradiated the left iliac artery with either 6 or 12 Gy using a focused external X-ray beam. At 28 days there were no significant differences in neointimal hyperplasia between the 6 Gy and control group; however, the 12 Gy-treated animals were found to have a statistically significant reduction in neointimal thickness when compared with controls, suggesting a dose-dependent response to external beam radiation.
More recent work in a porcine model highlights the importance of the animal model as well as appropriate dosimetry. Schwartz and colleagues 17 at the Mayo Clinic exposed groups of juvenile pigs to either no radiation, 40 Gy 1 day post-mechanical injury, 40 Gy at 1 and 4 days after injury, and 80 Gy 1 day after injury. Irradiation was delivered by an external X-ray source. They studied neointimal thickening at 28 days following external beam radiation. Schwartz found that external X-rays accentuated the injury and accelerated neointimal formation in a dosedependent fashion. Although the study was potentially compromised by the relatively high doses of radiation, the negative findings diminished enthusiasm for the use of external beam irradiation as a strategy for reducing restenosis.
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Intracoronary delivery of radiation: timing and dosing
Intracoronary delivery of radiation is clearly more attractive than external beam -it is site-specific and is likely to avoid systemic side effects of irradiation. However, it is invasive and involves the use of novel devices, including catheters and wires.
Wiedermann's group at Columbia investigated the use of pre-intervention intracoronary radiation in a porcine model. 18 Ten pigs were pretreated with a short train of 192 Ir seeds delivered within a catheter with dosimetry of 20 Gy to the target artery; subsequently, overstretch balloon injury was employed to induce vessel injury. Nine control pigs had balloon injury alone. At 30 days, the surviving 18 pigs were killed and the injured arteries examined. The mean neointimal area and area stenosis were significantly lower in the radiation-treated pigs, indicating that pretreatment with ␥-radiation could inhibit restenosis. A follow-up study by the Columbia group, using the same techniques, confirmed that neointimal inhibition was sustained for at least 6 months. 19 Waksman et al 20 used lower doses of ␥-radiation and found similar inhibition with a dose-dependent response. He administered 3, 5, 7, or 14 Gy to the target vessel immediately after balloon injury and discovered that intimal thickening was diminished at progressively higher doses of radiation compared with controls. To investigate the role of the proper timing of radiation, they administered 7 Gy 48 h after injury and found that intimal thickening was significantly decreased compared with similar pigs treated at the time of injury.
Weinberger's group expanded their investigations to determine the putative lower dose threshold for a stimulatory effect upon the intima by radiation. 10 They again used a porcine coronary model and preprocedure
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Ir ␥-radiation in doses of 10 or 15 Gy before balloon injury. They compared this experiment with 20 Gy-treated and control animals in a previous trial. 18 The neointimal area at 28 days was decreased significantly in the 15 Gy-treated group compared with controls. The 10 Gy-treated group had an increased intimal area, suggesting a stimulatory effect at this dose when delivered preprocedure.
Verin used a rabbit model to study the use of the ␤-emitter, 90 Y, delivered by coils within a centering catheter. 21 He delivered 6, 12, and 18 Gy to both carotid and iliac arteries that were mechanically denuded. Smooth muscle cells were labeled with bromodeoxyuracil (BrDU) and he measured the number of BrDU-labeled cells at 8 days. All groups had a statistically significant reduction in the number of labeled cells in the arterial media compared with controls. The 18 Gy group was the only group with a statistically significant reduction in counted cells in the neointima; however, at 6 weeks the 6 and 12 Gy groups did not differ from the control group with respect to labeled cells in the arterial media, while the 18 Gy group had a significant reduction in the counted cells and histologic percentage area stenosis. Similar work in juvenile pigs by Wilcox et al 22 showed that ␤-irradiation with a 90 Sr/Y source at the time of balloon injury prevented the proliferation of adventitial myofibroblasts and their migration into the neointima at doses of 14 and 28 Gy. The time course of cellular response to injury suggested that adventitial proliferation In vitro rat and began within 3 days post-injury while migration occurred shortly thereafter. At 7 days post-injury, the proliferating cells had migrated into the neointima and continued to proliferate. By 14 days, a healing wound, evidenced by ␣-actin production and fibrotic scarring, was noted. Radiation appeared to inhibit this early proliferation and migration, thus blunting the restenosis pathophysiology. Apoptosis, evidenced by terminal transferase-mediated UTP nick-end labeling (TUNEL), was not significantly different between the treated and untreated groups. These two studies imply that dose, timing of radiation, and the animal model may have profound effects upon the results.
Isotope-filled balloons
An alternative strategy for intravascular brachytherapy relies on balloons expanded with liquid or gas radiation sources. Makkar et al 23 reported the use of a 188 Re-filled balloon as a primary tool for brachytherapy. Rhenium-188 is a ␤-emitter with a half-life of 17 h. A porcine model in which the left anterior descending (LAD) or right coronary artery (RCA) were mechanically injured by a stent was studied. They delivered 14 Gy at a depth of 0.5 mm and subsequently employed quantitative angiography as well as IVUS to assess efficacy. At 30 days, angiographic stenosis, area stenosis and intimal area were significantly reduced with use of the ␤-emitting balloon compared with controls. Kim et al 24 used a catheter filled with 166 Ho in ballooninjured pigs. They delivered 9 and 18 Gy to a depth of 2 mm and examined the arteries 4 weeks later. Mean intimal thickness, intimal area, and smooth muscle proliferation were markedly reduced in the group receiving 18 Gy. The 9 Gy group did not differ significantly from controls. This study demonstrated the safety and efficacy of a balloon-delivered system while generating additional dosimetry data.
Waksman and co-workers 25 tested a 133 Xe gas-filled balloon in a balloon-injured porcine coronary model. A dose of 15 Gy measured at 0.25 mm from the balloon was delivered and the animals were studied at 2 weeks. The gasfilled balloon was effective in limiting absolute intimal thickness as well as measurements of intimal thickness corrected for the extent of injury.
Centering catheters
Radiation dosimetry is calculated using a radial projection from the emission source. This practice leads many to conclude that centering of the source(s) will play an important role in inhibiting restenosis and avoiding radiation-induced injury. If a source is not centered, part of the vessel may be damaged by radiation while the diseased target lesion may be undertreated. Because many plaques are eccentric, the importance of centering may not be trivial, especially with respect to the long-term consequences of over-and undertreating disease. Waksman et al 26 have studied the use of a centered catheter with a 90 Y source in a porcine model. The porcine coronary arteries were injured with balloon injury or stent implantation. A dose of 18 Gy was administered to a depth of 1 mm from the centering catheter. Two Vascular Medicine 1999; 4: 257-268 weeks after balloon injury and 4 weeks after stent injury, the arteries were examined, revealing that radiation was effective in minimizing intimal area compared with controls. When corrected for the extent of injury, the result was even more significant. In the group that received a stent, the late loss was decreased by 93%.
Stenting and adjunct radiation
When used in combination with coronary stents, intracoronary irradiation appears to be particularly effective in preventing restenosis in animals. When 14 Gy was administered with 90 Sr/Y seeds or an 192 Ir ribbon prior to stent implantation in a balloon-injured porcine coronary model, Waksman and colleagues found a significant decrease at 28 days in neointimal thickness in the irradiated groups compared with controls. 27 There was a slight difference in intimal areas in the two radiation groups, favoring ␥-radiation; however, the difference failed to have statistical significance. A comparison between stent-and balloon-injured pig coronary arteries pretreated with various doses of ␥-radiation from 192 Ir suggested no difference in neointimal hyperplasia inhibition at 28 days between the two types of injury. 9 In this study a dose-response curve was generated, indicating a minimal dose effectiveness of 15 Gy.
Radioactive stents
The feasibility, safety, and efficacy of radiation-emitting stents are currently being investigated. Fischell studied the effect of a low-dose 32 P ␤-emitting wire on cultured rat and human aortic smooth muscle cells, as well as bovine endothelial cells, and found doses as low as 0.006 Ci inhibited SMC growth. 28 Endothelial cells failed to demonstrate growth inhibition up to 0.019 Ci, implying greater radioresistance in these cells. Hehrlein et al 29 irradiated Palmaz-Schatz stents in a cyclotron and then implanted them into healthy rabbit iliac arteries. The stents had activities of 3.9, 17.5, or 35 Ci at the time of implantation and were designed to deliver a maximum dose of 16 Gy at a radius of 1 mm by 5 days post-implantation. Specimens were harvested at 1, 4, and 12 weeks and studied for the presence of SMC. When compared with controls (non-radioactive stents) and the lowest-dose irradiation, the group receiving the highest dose had a statistically significant decrease in neointimal thickness and smooth muscle cell counts at all follow-up time points, indicating a dose-dependent response. Endothelialization of the stents was delayed in the two highest dose groups, confirming the role of radiation in preventing cellular proliferation at the earlier time points. A follow-up study by these investigators, using 32 P stents with activities of 4 and 13 Ci, demonstrated that neointimal thickness was reduced when compared with inert 31 P stents at 4 and 12 weeks. Of note, the neointimal area in the 4 Ci group at 12 weeks, although smaller, was not significantly different from controls. 30 Laird et al 31 deployed
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P low-energy (0.14 Ci) ␤-emitting stents in iliac arteries of seven pigs and discovered that neointimal thickening and the percentage area stenosis were significantly decreased at 28 days compared with controls receiving a 31 P non-radioactive stent. The low dose neither delayed endothelialization nor significantly decreased SMC proliferation.
Carter et al performed further dose investigations with ␤-emitting stents. 32 They deployed 32 P stents with 0.15, 0.5, 1.0, 3.0, 14.0, and 23.0 Ci activity in pigs and studied the arteries at 28 days. All radioactive stents but one demonstrated a reduction in neointimal area and the percentage area stenosis compared with controls. Stents with an activity of 1.0 Ci, were associated with a significant increase in neointimal formation and lumen stenosis, suggesting a promotion of SMC activity at this dose. Rivard and colleagues also suggested that a 0.6 mCi 32 P-PalmazSchatz stent could be effective in preventing restenosis by limiting neointimal hyperplasia. 33 Accurate dosimetry calculations for radioactive stents are difficult. Weinberger et al 35 examined several different types of radioactive stents and compared their effective dosing. He placed an isotope-filled balloon within several types of stents and measured radiation outside the stent. There were significant differences in dose within 0.75 mm of the stent due to shielding from stent struts. At greater distances, scatter compensated for this shielding, yielding more uniform dose characteristics.
Summary of animal studies
Several animal models have been used to study the effects of radiation therapy on vascular structures. The best-studied models are the pig and rabbit. The value of external beam irradiation has been questioned because of marked variation in efficacy amongst species. Failure of external beam radiation in a pig model has largely abolished enthusiasm for this approach. The use of intracoronary brachytherapy in temporal relationship to percutaneous intervention has been extensively scrutinized. The preponderance of animal data suggest that intracoronary radiation can be delivered safely to a target vessel and can be effective in retarding restenosis. The ideal dosimetry may be dependent upon multiple factors, including centering and timing of delivery. Some data suggest lower doses may stimulate and promote intimal hyperplasia. 10, 32 Irradiated stents may also be useful in preventing restenosis; however, stent design is likely to have a crucial impact on dosimetry calculations. Animal studies will continue to pursue identification of the most appropriate isotope and its therapeutic window. Long-term and ultralong-term data on vascular integrity and late adverse effects need further definition.
Human trials of brachytherapy for restenosis (Table 2)
Several human clinical trials have yielded data on the value of brachytherapy as an anti-restenosis strategy. Initial studies focused on feasibility and safety. The number of patients treated is small but the results are encouraging. The majority of data are available only in abstract form -the larger trials are still in the enrollment phase. Human studies involving brachytherapy in peripheral iliac restenotic arteries, human arteriovenous hemodialysis shunts and corVascular Medicine 1999; 4: 257-268 onary arteries have been reported. Endovascular brachytherapy has been studied with both ␥-and ␤-emitting sources. Various delivery systems have evolved with both centering and non-centering strategies. Brachytherapy sources have been delivered from computer-controlled remote HDR afterloaders, hand-cranked manual afterloaders, and hydraulic injection devices.
External beam irradiation
External beam irradiation has been used to reduce cellular proliferation in keloid scars, Peyronie's disease, pterygia and many other 'benign' proliferative disorders. External beam irradiation has also been associated with late complications. Long-term follow-up of irradiated Hodgkin's disease patients reveals a high incidence of pericardial and coronary artery disease, particularly ostial stenoses. These late effects typically present 6-12 years post-irradiation. 50 The internal thoracic arteries can also be damaged by external beam radiation, leaving them unusable in bypass procedures. 51 Steidle 36 reported a 24 patient non-randomized study of external beam irradiation following successful intervention of occluded superficial femoral arteries. Eleven patients received 12.5 Gy in five consecutive 2.5-Gy fractions. Follow-up ranged from 6 to 15 months. Two patients required surgery and one had partial restenosis. Of the 13 controls, five needed surgery for reocclusion and three developed restenosis not requiring surgery. No immediate complications from the radiation treatment were encountered. Because of recognized long-term complications following external beam irradiation and the advent of endovascular radiation delivery systems, clinical interest has shifted to intracoronary brachytherapy.
Brachytherapy with gamma sources
Liermann and colleagues in Frankfurt, Germany were the first to use brachytherapy to prevent vascular restenosis. 37 They locally irradiated human femoral arteries using a ␥-source( 192 Ir) and reported low restenosis rates at 6 years. Waksman et al 38 have reported the short-term success of ␥-irradiation for restenosis post-angioplasty of dialysis arteriovenous graft stenoses. Eleven patients with 14 stenoses were given 14 Gy at a depth of 2 mm to the arterial wall using an 192 Ir line source delivered by an HDR afterloader. Mean follow-up was 164 ± 36 days. Patency was demonstrated on ultrasound study in 13/14 (93%) grafts, with one graft thrombosis at 3 months post procedure; however, after 18 lesions were treated, 4 (22%) exhibited restenosis at a mean follow-up of 44 weeks. 52 Condado et al 39 reported 21 patients (22 arteries) treated after coronary angioplasty demonstrating the feasibility and relative safety of this therapy. A non-centered 30-mm long 192 Ir source wire with a 4-French monorail delivery catheter was used in their study. Intended doses of 18-25 Gy were utilized (actual dose 7.2-92.5 Gy). Quantitative angiographic follow-up was performed at 24 h and 30-60 days. At the later follow-up, two arteries were found to be occluded, a new pseudoaneurysm was found in another and significant dilatation was seen in two arteries. Mean late lumenal loss was 0.27 ± 0.56 mm, and the mean late loss index was 0.19 for the treated arteries. At 1 year followup, there was one incident of myocardial infarction. Repeat PTCA was required in three patients and seven had persistent angina. At 2 years follow-up, 40 the restenosis rate was 28% and four patients (19%) developed pseudoaneurysms (two early and two late), with a mean late loss index of 0.26.
The SCRIPPS (Scripps Coronary Radiation to Inhibit Proliferation Post-Stenting) trial 8 demonstrated that ␥-irradiation, in stented coronary vessels, significantly reduced restenosis without major adverse events in the first 6 months. This trial was a double-blind placebo-controlled randomized study using a 0.76-mm non-centered ribbon containing sealed 192 Ir sources or placebo to treat restenotic lesions in 3-5-mm vessels. A total of 55 patients were enrolled and 26 received radiation. A dose of 8 Gy was delivered to the target (leading edge of tunica media) farthest from the source and Յ30 Gy to the target nearest to the source. Intravascular ultrasound and quantitative coronary angiography were obtained at baseline and 6 months. Angiographic follow-up was performed in 53 patients (96%) at a mean interval of 6.7 ± 2.2 months. At followup the minimal lumen diameter (MLD) was significantly larger in the treated group (2.43 ± 0.78 mm versus 1.85 ± 0.89 mm; p = 0.02). Late lumenal loss was significantly lower in the 192 Ir group (0.38 ± 1.06 mm versus 1.03 ± 0.97 mm; p = 0.03). Angiographic restenosis occurred in 17% of the treated patients and 54% in the placebo group (p = 0.01). No complications were reported.
The SCRIPPS II study 41 randomized 51 patients with diffuse coronary restenosis up to 65 mm long to 192 Ir or placebo. There were no major adverse cardiac events (MACE) at 30 days. Two patients had partially obstructed flow from the catheter requiring treatment interruption, with the source wire withdrawn in less than 20 s.
The WRIST (Washington Radiation for In-Stent restenosis Trial) study 42 was a recently completed double-blind randomized trial in 130 patients with in-stent restenosis (Ն1 episode, mean 3.5). A total of 100 patients had instent restenosis in a native vessel and 30 had in-stent restenosis in a saphenous vein graft. Patients were treated with a debulking strategy (PTCA, laser, or high-speed rotational atherectomy) with adjunct stenting where indicated. An 192 Ir ribbon or placebo was delivered within a non-centered 5 F catheter. A dose of 15 Gy was delivered at a radial distance of 2 mm from the center of the source. Crossover to brachytherapy was allowed in patients assigned to the placebo arm if restenosis was found at follow-up. The 6-month target lesion revascularization (TLR) and target vessel revascularization (TVR) rates were 14% and 29% in the radiation-treated group; the control group had 63% and 68%, respectively. Some 19% of radiation-treated patients and 58% of control group patients exhibited restenosis defined as Ն50% stenosis by angiography. A combined endpoint of mortality, repeat TLR and acute MI was reduced by 63% with radiation treatment.
PARIS (Peripheral Artery Radiation Investigational Study) is a Phase II international multicenter trial to evaluate 192 Ir brachytherapy in superficial femoral artery restenosis following angioplasty. A total of 300 patients with lesions 5-15 cm in length will be randomized in a doubleblind fashion to 14 Gy delivered to the adventitia defined Vascular Medicine 1999; 4: 257-268 as the radius of the centering catheter plus 2 mm, with the aim to reduce restenosis by 30% at 12 months. A segmented centering catheter will be used to deliver the gamma sources.
Brachytherapy with beta irradiation
In the Swiss yttrium study, Verin et al 43 described that their first 15 patients received ␤-radiation for inhibition of coronary restenosis. This small feasibility study failed to demonstrate a significant advantage with brachytherapy. A 90 Y source was centered using a 30-mm long segmented balloon with four interconnected compartments mounted on a double lumen plastic shaft with an internal (source) blind lumen diameter of 0.40 mm. A dose of 18 Gy was delivered to the inner arterial surface; four patients had stents. The mean follow-up was 178 × 17 days. No complications were attributable to irradiation. Six of the 15 patients (40%) had angiographic restenosis and 4 (27%) needed target vessel revascularization (TVR). There was no impact on restenosis, although the system was found to be easily deliverable.
IRIS (Isostent for Restenosis Interventional Study) 44 was the first trial to explore the antirestenotic potential of a ␤-emitting radioactive stent (IsoStent; J&J/Cordis, Miami, FL, USA). In this non-randomized investigation, 32 patients had 32 P-labeled Palmaz-Schatz stents (0.5-1.0 Ci) implanted in 22 de novo and 10 restenotic lesions. Primary endpoints were safety and absence of death, Q-wave myocardial infarction, emergency CABG, target lesion revascularization or neutropenia. The minimum stent crosssectional area was 7.6 ± 2.1 mm 2 . Binary instent restenosis occurred in 10 patients (31%) and was not different from incidence of restenosis in patients treated with non-radioactive stents.
Because of the inconclusive results in the first phase of IRIS, the IRIS Feasibility Study 45 used higher-dose 32 P-labeled Palmaz-Schatz stents (0.75 Ci to 1.50 Ci) with an average activity of 1.06 Ci. A total of 27 IsoStents were deployed successfully in 22 de novo and three restenotic lesions in 25 patients. At 30 days, there were no MACE. Further follow-up data are unavailable at this time.
BERT (Beta Radiation Restenosis Trial) 46 was the first trial in the USA to use a ␤-emitter source ( The restenosis rate at 6 months was 24.7%, including an edge restenosis rate of 7.7%. The late-loss index was 0.08. Interestingly, IVUS data from the Canadian arm of BERT revealed that 16/26 patients had dissections post-procedure; of these, seven had unresolved dissections at the 6-month follow-up although three had an improvement in the degree of dissection. 47 This finding suggests that post-injury healing may be impaired by radiation therapy.
PREVENT (Proliferation REduction with Vascular ENergy Trial) 48 is a prospective randomized, blinded multicenter trial to assess the safety and efficacy of the Guidant VI Brachytherapy system post-coronary angioplasty or stenting. This system uses a spiral centering balloon and an HDR afterloader. Radiation is delivered with a 32 P ␤-emitting source wire. Target lesions include de novo and restenotic lesions, with and without stents, in native coronary vessels. Lesion lengths were limited to 15 mm or less. Recent myocardial infarction, vein graft lesions, atherectomy and left main stenosis were excluded. This Phase I trial enrolled 72 patients at three sites: Baylor, Stanford, and the Washington Hospital Center. Patients were randomized to doses of 0, 16, 20, and 24 Gy at 1.0 mm into the vessel wall. The interventionists were blinded to the assigned dose. Enrollment was completed in May 1998. Six-month angiograms and IVUS were mandated by protocol. Early results from PREVENT 49 have found equivalent restenosis rates in patients who received radiation and those who did not (24% versus 22%). Interestingly, the restenosis rate in radiation-treated lesions was only 6%; however, at the edges of the treatment zone, the restenosis rate was 18%, suggesting a possible edge effect related to the dropoff in radiation dose. Further analysis is currently underway.
A recent study using a 188 Re balloon for in-stent restenosis found that of 26 patients treated with 18 Gy to 1 mm deep from the balloon/intimal interface, five (19%) patients had restenosis. Of these five, four had edge effects. All five underwent target vessel revascularization.
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Discussion
Although enthusiasm for brachytherapy is strong, many questions are unanswered. A small number of patients have been studied. The heterogeneity of treated lesions (de novo, restenotic, instent or graft), variety of associated interventions (atherectomy, stent, angioplasty alone) and dosimetry variations preclude generalized observations. Data from the SCRIPPS trial suggest ␥-radiation has short-term (6 months) efficacy for inhibiting restenosis; however, ␥-radiation is potentially fraught with hazards to the operator and patient. In the SCRIPPS trial, dwell times were 20-45 min, during which time physicians and staff left the catheterization laboratory while a radiation oncologist hand-delivered the radioactive source train.
Beta-radiation has markedly diminished penetration compared with gamma sources. Use of a ␤-emitter results in less incidental irradiation to surrounding tissues and significant reduction in exposure to the staff; however, dosimetry calculations are more difficult and centering of the source may be crucial. There is evidence that centering is also desirable with ␥-irradiation to reduce dose heterogeneity. 54 It is difficult to know whether a source is truly centered in a vessel, even with a centering catheter. The inherent eccentricity of plaque and vessel-deforming calcification may require debulking of coronary lesions, prior to brachytherapy, to achieve uniform dosimetry. There are few long-term safety data and concerns over radiation-induced carcinogenesis and aneurysm formation are unassuaged. The possible ␥-irradiation-induced pseudoaneurysm formation in the Caracas study 39, 40 may be related to the lack of centering, with high radiation doses to the nearest wall of Vascular Medicine 1999; 4: 257-268 the target area. Vessel calcification 55 and stents 35 may shield the target arterial wall from the effective radiation dose (particularly if ␤ sources are used). Different stents may also have distinct attenuation effects on brachytherapy. 27 Finally, the clinical data from PREVENT has suggested that there may be an important edge effect ('candywrapper') with the use of ␤-radiation related to the dose drop-off and proliferative stimulation, supporting earlier animal work as well as more recent data with a 188 Re balloon in both humans 53 and animals. 56 The appropriate target of brachytherapy is unknown and it is therefore reasonable to treat all the likely target cells in the media and adventitia; such a strategy, however, may lead to overtreatment in the media or undertreatment in the adventitia.
The use of IVUS has been advocated over quantitative coronary angiography (QCA) for measuring the effect of brachytherapy in clinical trials. Intravascular ultrasound facilitates analysis of the anatomical substrate and the complex 3-D morphology of coronary vessels 56 so that accurate late loss indices can be calculated.
The indications for brachytherapy remain undefined. 57 Should all patients have adjunct brachytherapy following their initial intracoronary interventions, or should brachytherapy be reserved for lesions with repetitive restenosis? Will brachytherapy obviate the need for routine stenting as an antirestenosis strategy? These questions will necessarily be answered in the context of ongoing multicenter trials. The ultimate utilization of brachytherapy will need to be reconciled with demonstrated safety and a favorable costeffective profile.
